摘要
众所周知,唐氏综合症患者到中年在神经病理学上发展为阿尔茨海默病。阿尔茨海默病和唐氏综合征,都伴随着对基底前脑胆碱能神经元神经生长因子(NGF)依赖性萎缩。阿尔茨海默病神经生长因子的营养危害很早被怀疑,这一假设因阿尔茨海默氏病的尸检发现大脑里不变的NGF mRNA合成与增长的神经生长因子前体水平(proNGF)而被否认。神经生长因子营养断开的可能性最近因细胞外因子代谢途径的新发现而被重新审视;在此途径proNGF以功能依赖性方式释放和在细胞外空间被血纤维蛋白溶酶转化成熟的NGF。成熟的NGF最终是由金属蛋白酶MMP-9降解。这条途径已被显示出阿尔茨海默氏症和唐氏综合症的大脑里的损害,从而用恢复营养因子假说来解释这类疾病的基底前脑胆碱能神经元的萎缩。本章将探讨NGF的生理作用及它对中枢胆碱能神经元的生物学意义,并提出证据证明阿尔茨海默病和唐氏综合征中的NGF代谢失调。
关键词: Alzheimer's disease
Current Alzheimer Research
Title:The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Volume: 13 Issue: 1
Author(s): M. Florencia Iulita and A. Claudio Cuello
Affiliation:
关键词: Alzheimer's disease
摘要: It is well established that individuals with Down syndrome develop Alzheimer’s disease neuropathology by middle age. Both in Alzheimer’s disease and Down syndrome, this is accompanied by the atrophy of NGF-dependent cholinergic neurons of the basal forebrain. An NGF trophic compromise in Alzheimer’s disease had been early suspected. This hypothesis was discarded with the finding of unaltered NGF mRNA synthesis and of increased NGF precursor levels (proNGF) in postmortem Alzheimer’s disease brains. The possibility of an NGF trophic disconnection has been recently revisited at the light of a newly discovered extracellular NGF metabolic pathway; where proNGF is released in an activity-dependent manner and converted by plasmin to mature NGF in the extracellular space. Mature NGF is ultimately degraded by the metalloprotease MMP-9. This pathway has been shown to be compromised in Alzheimer’s disease and Down syndrome brains, thus reviving the trophic factor hypothesis to explain the atrophy of basal forebrain cholinergic neurons in these disorders. This chapter will discuss the physiological role of NGF and its biological significance to cholinergic neurons of the CNS, and present the evidence for a dysregulation of the NGF metabolism in Alzheimer’s disease and Down syndrome.
Export Options
About this article
Cite this article as:
M. Florencia Iulita and A. Claudio Cuello , The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (1) . https://dx.doi.org/10.2174/1567205012666150921100030
DOI https://dx.doi.org/10.2174/1567205012666150921100030 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Signal Transduction Therapy Lipid Based Anti-Retroviral Nanocarriers: A Review of Current Literature and Ongoing Studies
Drug Delivery Letters Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology Recent Developments in Receptor-Selective Retinoids
Current Pharmaceutical Design Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Animal Models of Systemic Sclerosis
Current Pharmaceutical Design The Epigenetics of Breast Carcinogenesis and Metastasis
Current Genomics Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors
Current Medicinal Chemistry Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Immobilization and Application of Electrospun Nanofiber Scaffold-based Growth Factor in Bone Tissue Engineering
Current Pharmaceutical Design